AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20112484 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Bushen Koufuye combined with chemotherapy
Number of subjects: 47
Study 20112484 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control group)
Number of subjects: 47
Study 16675812 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal quinine (20 mg/kg diluted to 30 mg/ml in water solution)
Number of subjects: 898
Study 16675812 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular quinine (12.5 mg/kg)
Number of subjects: 898
Study 14754569 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent consumption of sport-caught fish
Number of subjects: 1481
Study 14754569 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent consumption of Great Lakes fish
Number of subjects: 1481
Study 14754569 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent consumption of sport-caught fish (for premenopausal women)
Number of subjects: 1481
Study 11596838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 88 microg twice daily
Number of subjects: 451
Study 11596838 — intervention group
Group type: COMPARATOR
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 451
Study 9230654 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin started postoperatively
Number of subjects: 316
Study 9230654 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin started preoperatively
Number of subjects: 316
Study 7604802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day plus cholestyramine 4 g/day
Number of subjects: 144
Study 7604802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day plus cholestyramine 8 g/day
Number of subjects: 144
Study 7604802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day plus cholestyramine 16 g/day
Number of subjects: 144
Study 7604802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin plus cholestyramine (all doses)
Number of subjects: 144
Study 2243890 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-watt bedside light
Number of subjects: 16
Study 2243890 — intervention group
Group type: COMPARATOR
Intervention: Dim red placebo (photographic safe light)
Number of subjects: 16
Study 345423 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of cephradine orally twice daily (b.i.d.)
Number of subjects: 548
Study 345423 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of cephradine given 4 times a day (q.i.d.)
Number of subjects: 548
Study 31068270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir, emtricitabine, and tenofovir alafenamide (n=314)
Number of subjects: 631
Study 31068270 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir, abacavir, and lamivudine (n=315)
Number of subjects: 631
Study 31068270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir, emtricitabine, and tenofovir alafenamide
Number of subjects: 631
Study 31068270 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir, abacavir, and lamivudine
Number of subjects: 631
Study 27817944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus paclitaxel
Number of subjects: 481
Study 27817944 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 481
Study 26417459 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal electrical stimulation (ES) assisted fast goal-directed wrist extension training
Number of subjects: 0
Study 26417459 — intervention group
Group type: COMPARATOR
Intervention: General health education
Number of subjects: 0
Study 24615239 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing energy drink (3 mg of caffeine/kg)
Number of subjects: 18
Study 24615239 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (no caffeine)
Number of subjects: 18
Study 22713626 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment with flecainide (200-300 mg per day for 4 weeks)
Number of subjects: 524
Study 22713626 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with flecainide (for 6 months)
Number of subjects: 524
Study 22713626 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drug treatment (control)
Number of subjects: 524
Study 20634186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (30 mg, oral)
Number of subjects: 35
Study 20634186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17468493 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: BIS 45(5), remifentanil 1 ng ml(‐1)
Number of subjects: 95
Study 17468493 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: BIS 45(5), remifentanil 2 ng ml(‐1)
Number of subjects: 95
Study 17468493 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: BIS 45(5), remifentanil 4 ng ml(‐1)
Number of subjects: 95
Study 17468493 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: BIS 30(5), remifentanil 2 ng ml(‐1)
Number of subjects: 95
Study 17468493 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5: BIS 60(5), remifentanil 2 ng ml(‐1)
Number of subjects: 95
Study 17468493 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstimulated HRV
Number of subjects: 95
Study 17468493 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation-induced HRV
Number of subjects: 95
Study 15123461 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative intraperitoneal chemotherapy (EPIC) plus systemic chemotherapy after complete cytoreductive surgery
Number of subjects: 35
Study 15123461 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy alone after complete cytoreductive surgery
Number of subjects: 35
Study 12469979 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modified release capsule of mebeverine
Number of subjects: 12
Study 12469979 — intervention group
Group type: COMPARATOR
Intervention: 135 mg plain tablet of mebeverine
Number of subjects: 12
Study 9306300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine receptor antagonists (haloperidol or fluphenazine)
Number of subjects: 0
Study 9306300 — intervention group
Group type: COMPARATOR
Intervention: Control group (heavy cocaine users who were not mentally ill)
Number of subjects: 0
Study 8442962 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg/kg
Number of subjects: 24
Study 8442962 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 24
Study 8442962 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 3537635 — intervention group
Group type: EXPERIMENTAL
Intervention: guanfacine (0.5 mg/day)
Number of subjects: 11
Study 3537635 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 30135020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose modification (adjustment or treatment delay)
Number of subjects: 738
Study 30135020 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF) use in dose-modified patients
Number of subjects: 738
Study 30135020 — intervention group
Group type: COMPARATOR
Intervention: No dose modification (referent group)
Number of subjects: 738
Study 25935320 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS plus opioids (Group 1)
Number of subjects: 56
Study 25935320 — intervention group
Group type: COMPARATOR
Intervention: Opioids alone (Group 2)
Number of subjects: 56
Study 25935320 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 56
Study 25460150 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized buccoadhesive patches containing Tizanidine hydrochloride (TIZ) incorporated into Compritol-based hot-melts.
Number of subjects: 0
Study 25460150 — intervention group
Group type: COMPARATOR
Intervention: Immediate release tablet Sirdalud® (control).
Number of subjects: 0
Study 22852579 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26576 at 450 mg bid in MDD patients
Number of subjects: 90
Study 22852579 — intervention group
Group type: COMPARATOR
Intervention: Org 26576 in healthy volunteers (HVs)
Number of subjects: 90
Study 22852579 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26576
Number of subjects: 90
Study 20172704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide/albuterol Respimat inhaler (20/100mcg)
Number of subjects: 1209
Study 20172704 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide/albuterol MDI (36mcg/206mcg)
Number of subjects: 1209
Study 20172704 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium Respimat inhaler (20mcg)
Number of subjects: 1209
Study 17490960 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 10
Study 16287351 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive training and high-resistance interval training (12 sessions of 30 minutes each)
Number of subjects: 18
Study 16287351 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 18
Study 12466869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative skin traction
Number of subjects: 311
Study 12466869 — intervention group
Group type: COMPARATOR
Intervention: No pre-operative skin traction (Control)
Number of subjects: 311
Study 11107572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ischemic stroke patients
Number of subjects: 40
Study 11107572 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe ischemic stroke patients
Number of subjects: 40
Study 11107572 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 40
Study 8669601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg plus diazepam 10 mg
Number of subjects: 121
Study 8669601 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets plus diazepam 10 mg
Number of subjects: 121
Study 8669601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 121
Study 8669601 — intervention group
Group type: COMPARATOR
Intervention: Cisapride and placebo
Number of subjects: 121
Study 1776177 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative health campaign via media and general practitioners for 16 weeks
Number of subjects: 20
Study 1776177 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 general practitioners)
Number of subjects: 20
Study 6976822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal ischemia cases following aortic surgery
Number of subjects: 10
Study 31762443 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 238
Study 31762443 — intervention group
Group type: COMPARATOR
Intervention: Control (sham RIPC procedure)
Number of subjects: 238
Study 28884737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (reflexotherapy) combined with pharmacotherapy and psychologist's recommendations
Number of subjects: 30
Study 28884737 — intervention group
Group type: COMPARATOR
Intervention: Medication therapy and psychotherapy without acupuncture
Number of subjects: 30
Study 25805718 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical exercises
Number of subjects: 96
Study 25805718 — intervention group
Group type: COMPARATOR
Intervention: Sham exercises
Number of subjects: 96
Study 25886327 — intervention group
Group type: EXPERIMENTAL
Intervention: Group FPM (IV fortwin 0.3 mg/kg over 1 min + IV midazolam 0.04 mg/kg + IV phenergan 12.5 mg)
Number of subjects: 50
Study 25886327 — intervention group
Group type: COMPARATOR
Intervention: Group KM (IV ketamine 0.3 mg/kg over 1 min + IV midazolam 0.04 mg/kg)
Number of subjects: 50
Study 25886327 — intervention group
Group type: EXPERIMENTAL
Intervention: Group FPM
Number of subjects: 50
Study 25886327 — intervention group
Group type: COMPARATOR
Intervention: Group KM
Number of subjects: 50
Study 22960436 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine plus vitamin D
Number of subjects: 43
Study 22960436 — intervention group
Group type: COMPARATOR
Intervention: Memantine alone
Number of subjects: 43
Study 22960436 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D alone
Number of subjects: 43
Study 19765321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate applied once or twice a day
Number of subjects: 175
Study 19765321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle alone)
Number of subjects: 175
Study 17534818 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol HCl 0.25% suspension
Number of subjects: 15
Study 17534818 — intervention group
Group type: COMPARATOR
Intervention: Topical betaxolol HCl 0.50% solution
Number of subjects: 15
Study 15572894 — intervention group
Group type: EXPERIMENTAL
Intervention: Concanavalin A stimulation during antigen elimination diet
Number of subjects: 35
Study 15572894 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cow's milk challenge
Number of subjects: 35
Study 11339466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg IV 5 min before placement of the MH
Number of subjects: 45
Study 11339466 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain lidocaine 3 ml 1% by infiltration at each pin site 1 minute before placement
Number of subjects: 45
Study 11339466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and lidocaine combined (FL group)
Number of subjects: 45
Study 9725482 — intervention group
Group type: EXPERIMENTAL
Intervention: Two suppositories of 500 mg
Number of subjects: 0
Study 9725482 — intervention group
Group type: EXPERIMENTAL
Intervention: One suppository of 1000 mg
Number of subjects: 0
Study 9725482 — intervention group
Group type: COMPARATOR
Intervention: Two tablets of 500 mg
Number of subjects: 0
Study 7989938 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 52
Study 7989938 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 52
Study 2483828 — intervention group
Group type: EXPERIMENTAL
Intervention: IV immunoglobulins (IVI)
Number of subjects: 20
Study 2483828 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 48054 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 39
Study 48054 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 31555824 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ vaccine (doses: 1.35 × 10^5, 2.7 × 10^5, 4.5 × 10^5, 9.0 × 10^5, and 1.8 × 10^6) administered by direct venous inoculation (DVI)
Number of subjects: 156
Study 31555824 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ vaccine (doses: 9.0 × 10^5 and 1.8 × 10^6)
Number of subjects: 156
Study 31555824 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 156
Study 30612110 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm Cycle Ergometry Training (ACET)
Number of subjects: 60
Study 30612110 — intervention group
Group type: COMPARATOR
Intervention: Body Weight-Supported Treadmill Training (BWSTT)
Number of subjects: 60
Study 30612110 — intervention group
Group type: EXPERIMENTAL
Intervention: ACET
Number of subjects: 60
Study 30612110 — intervention group
Group type: COMPARATOR
Intervention: BWSTT
Number of subjects: 60
Study 28391437 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron (IV ferric gluconate 125 mg weekly for 8 weeks)
Number of subjects: 64
Study 28391437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrosomial iron (30 mg daily for 8 weeks)
Number of subjects: 64
Study 28391437 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron (IV ferric gluconate)
Number of subjects: 64
Study 28391437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrosomial iron
Number of subjects: 64
Study 28391437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrosomial oral iron
Number of subjects: 64
Study 28391437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 64
Study 25358490 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of a polyphenol-rich treatment extracted from fruit and vegetables (Mediterranean diet) daily for 12 weeks
Number of subjects: 0
Study 24186595 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg BID (n = 40)
Number of subjects: 80
Study 24186595 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine once daily (n = 40)
Number of subjects: 80
Study 24186595 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg BID
Number of subjects: 80
Study 24186595 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine once daily
Number of subjects: 80
Study 21990399 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP(escalated)
Number of subjects: 1670
Study 21990399 — intervention group
Group type: COMPARATOR
Intervention: 4 + 4 BEACOPP (4 cycles of BEACOPP(escalated) followed by 4 cycles of BEACOPP(baseline))
Number of subjects: 1670
Study 21990399 — intervention group
Group type: COMPARATOR
Intervention: 4 + 4 BEACOPP
Number of subjects: 1670
Study 21990399 — intervention group
Group type: EXPERIMENTAL
Intervention: Without RT
Number of subjects: 1670
Study 21990399 — intervention group
Group type: COMPARATOR
Intervention: With RT
Number of subjects: 1670
Study 21990399 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with residual disease after chemotherapy
Number of subjects: 1670
Study 21990399 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bulk in complete response after chemotherapy
Number of subjects: 1670
Study 18434722 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg kg(‐1) min(‐1) MTR‐105 (M50, n = 12)
Number of subjects: 36
Study 18434722 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg kg(‐1) min(‐1) MTR‐105 (M10, n = 12)
Number of subjects: 36
Study 18434722 — intervention group
Group type: COMPARATOR
Intervention: Buffered phosphate solution (placebo control, n = 12)
Number of subjects: 36
Study 17075117 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 plus fluorouracil 750 mg/m2/d (DCF)
Number of subjects: 445
Study 17075117 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 plus fluorouracil 1,000 mg/m2/d (CF)
Number of subjects: 445
Study 14533136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 36
Study 14533136 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 36
Study 14533136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10901181 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (doses slowly escalating to achieve hematocrit of 42+/‐3%)
Number of subjects: 31
Study 10901181 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained at hematocrit of 30+/‐3%
Number of subjects: 31
Study 8837186 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot spinal anesthesia with 1% hyperbaric bupivacaine (0.27 mg/kg)
Number of subjects: 26
Study 8837186 — intervention group
Group type: COMPARATOR
Intervention: Incremental 5-mg bolus of 1% hyperbaric bupivacaine via a subarachnoid 32-gauge microcatheter every 10 minutes
Number of subjects: 26
Study 8837186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SSA and CSA)
Number of subjects: 26
Study 1570381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg oral diazepam
Number of subjects: 48
Study 1570381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3919611 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 55
Study 3919611 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 55
Study 30561775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance until disease progression
Number of subjects: 73
Study 29781932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intermediate cervical plexus block with 0.25% ropivacaine (0.2 mL/kg)
Number of subjects: 32
Study 29781932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intermediate cervical plexus block
Number of subjects: 32
Study 29781932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 32
Study 26616644 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate 70 mg · kg(‐1)
Number of subjects: 150
Study 26616644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg · kg(‐1)
Number of subjects: 150
Study 26616644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 3 μg · kg(‐1)
Number of subjects: 150
Study 25238873 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weekly regular early specialist symptom control care
Number of subjects: 174
Study 25238873 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 174
Study 21890793 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 579
Study 21890793 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication plus behavioral therapy
Number of subjects: 579
Study 21890793 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapy
Number of subjects: 579
Study 21890793 — intervention group
Group type: COMPARATOR
Intervention: Usual community treatment
Number of subjects: 579
Study 21890793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative stimulant exposure
Number of subjects: 579
Study 20978408 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory‐based, structured Hip Fracture Prevention Web site
Number of subjects: 245
Study 20978408 — intervention group
Group type: COMPARATOR
Intervention: Conventional Web sites
Number of subjects: 245
Study 18398460 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose sulphadoxine-pyrimethamine (SP)
Number of subjects: 1030
Study 18398460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study 15543180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume anaesthetic solution (2.8 ml)
Number of subjects: 39
Study 15543180 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 ml anaesthetic solution)
Number of subjects: 39
Study 12584831 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus injection (AI)
Number of subjects: 108
Study 12584831 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 108
Study 10723884 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete Fourier Transform (DFT)
Number of subjects: 40